Metastatic involvement of the penis is rare. About 80% of secondary lesions originate from pelvic primary tumors, mainly bladder and prostate. We present a case of prostatic mucinous adenocarcinoma with penile metastasis symptomatic for pain, which was treated with external-beam radiation (35 Gy/14 fractions; 2.5 Gy daily) combined with androgen deprivation, resulting in complete pain relief and objective response after treatment.
ChauxA., AminM., CubillaA.L., YoungR.H.: Metastatic tumors to the penis: a report of 17 cases and review of the literature. Int J Surg Pathol, 19: 597–606, 2011.
2.
Ben-YosefR., KappD.S.: Cancer metastatic to the penis: treatment with hypothermia and radiation therapy and review of the literature. J Urol, 148: 67–71, 1992.
3.
MugharbilZ.H., ChildsC., TannenbaumM., SchapiraH.: Carcinoma of prostate metastatic to penis. Urology, 25: 314–315, 1995.
4.
SönmezN.C., Co kunB., ArisanS., GüneyS., DalkiliçA.: Early penile metastasis from primary bladder cancer as the first systemic manifestation: a case report. Cases J, 2: 7281, 2009.
ChanP., BeginL.R., ArnoldD., JacobsonS.A., CorcosJ., BrockG.B.: Priapism secondary to penile metastasis: a report of two cases and a review of literature. J Surg Oncol, 68: 51–59, 1998.
10.
CherianJ., RaoA.R., ThwainiA., KapasiF., ShergillI.S., SammanR.: Medical and surgical management of priapism. Postgrad Med J, 82: 89–94, 2006.
11.
YuanJ., DesouzaR., WestneyO.L., WangR.: Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl, 10: 88–101, 2008.
12.
MukamelE., FarrerJ., SmithR.B., DekernionJ.B.: Metastatic carcinoma to penis: when is total penectomy indicated?Urology, 29: 15–18, 1987.
13.
HammF.C., WeinbergS.R.: Secondary malignant infiltration of the penis: report of four cases, two with surgical treatment for palliation. J Urol, 73: 149–154, 1955.
14.
Al-MamganiA., van PuttenW.L., HeemsbergenW.D., van LeendersG.J., SlotA., DielwartM.F., IncrocciL., LebesqueJ.V.: Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 72: 980–988, 2008.
15.
FiandraC., FilippiA.R., CatuzzoP., BotticellaA., CiammellaP., FrancoP., BorcaV.C., RagonaR., TofaniS., RicardiU.: Different IMRT solutions vs 3D-conformal radiotherapy in earlystage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol, 7: 186, 2012.
16.
AlongiF., De BariB., FrancoP., CiammellaP., ChekrineT., LiviL., Jereczek-FossaB.A., FilippiA.R.; on behalf of AIRO Young and AIRO Prostate Cancer Working Group: The ‘PROCAINA (PROstate CAncer INdications Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med, 118: 660–678, 2013.
17.
De BariB., AlongiF., FrancoP., CiammellaP., ChekrineT., LiviL., Jereczek-FossaB.A., FilippiA.R.; on behalf of AIRO Young and AIRO Prostate Cancer Working Group: The ‘PROCAINA (PROstate CAncer INdications Attitudes) Project (Part II): a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med, 118: 1220–1239, 2013.
18.
MunozF., FiandraC., FrancoP., GuarneriA., CiammellaP., De StefanisP., RondiN., MorettoF., BadellinoS., IftodeC., RagonaR., RicardiU.: Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med, 117: 1057–1070, 2012.
